HMGB1 and schistosomiasis: We envision a model (Figure 8) where anti-HMGB1 drugs would lead to an efficacious control of schistosomotic liver fibrosis, as follows: during acute schistosomiasis, secreted egg toxins, and antigens trigger a potent immune reaction and inflammatory response that lead to hepatic tissue damage.